Last updated on April 2018

Efficacy of Omega-3 as Adjunctive Therapy for Medically Intractable Epilepsy: A Prospective Open-label Pilot Study

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Epilepsy
  • Age: Between 20 - 70 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients with medically intractable, focal or generalized, epilepsy: Patients with localization-related partial onset or generalized tonic/clonic seizure according to the International League Against Epilepsy (ILAE) can be included. Medically intractable epilepsy means that recurrent seizures occur even though two or more anti-epileptic drugs have been used appropriately for over one year.
  • Seizure frequency criteria: three seizures per one month for recent 3 months before enrollment
  • Seizure criteria: simple partial, complex partial, or tonic-clonic seizures
  • Subjects with normal cognitive function: patients who can perform normal daily life. If not definite, enrollment will be done with K-MMSE score over 27.

Exclusion Criteria:

  • Poor general medical condition: comorbid with heart, lung, liver diseases
  • Patients who have history of pseudo-seizure
  • Anti-epileptic drugs has been changed in recent one month.
  • Chronic alcoholic
  • Seizure count cannot be done since seizures occur successively.
  • Allergy to fish
  • High risk of bleeding such as trauma or operation
  • Liver function abnormality
  • Pregnant or lactating women, or women who plans to have children
  • Patients who have participated in the other clinical trial in recent one month

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.